[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.89.187. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
August 8, 1966

Thyrocalcitonin Used In Clinical Trials

JAMA. 1966;197(6):35-36. doi:10.1001/jama.1966.03110060015004
Abstract

Early human studies substantiate thyrocalcitonin's theorized value as a preventive force in bone resorption.

Data from both England and France increase hope that the newly-isolated thyroid hormone has clinical value, the American Society for Pharmacology and Experimental Therapeutics was told recently.

In addition, a deeper understanding of the substance has shown it to be the product of a "previously unrecognized" secretory system within the thyroid.

"Although thyrocalcitonin's clinical value in treating osteoporosis, for instance, is still theoretical... it has upset completely the traditional view of calcium homeostasis," Alexander D. Kenny, PhD, commented for JAMAMedical News.

Dr. Kenny chaired a special symposium on thyrocalcitonin at the ASPET meeting in Mexico City. He is professor of pharmacology at West Virginia University School of Medicine.

In 1962, investigators at the University of British Columbia published evidence for a factor tending to lower blood calcium levels. However, the Canadians believed it came

×